New Haven drug developer Achillion Pharmaceuticals Inc. released additional positive safety and efficacy data from a mid-stage trial of its experimental HIV drug, Reuters reports.
Achillion’s drug elvucitabine, an L-cytosine nucleoside analog reverse transcriptase inhibitor (NRTI), had earlier shown potent in vitro antiviral activity against HIV, including strains resistant to other NRTIs, Reuters said.
NRTI is a class of drugs for use in HIV combination therapy.
After 96 weeks of treatment, patients taking elvucitabine once daily showed a substantial anti-viral effect similar to already approved NRTI 3TC.
The drug was well-tolerated and showed a safety profile comparable to 3TC for both incidence and severity of adverse events, the company said.
At mid-morning, Achillion fell 5 cents, or 2.1 percent, at $2.34.
